Posted by Michael Wonder on 31 Oct 2024
Leniolisib phosphate for the treatment of patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome
31 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of leniolisib phosphate in the NHS in England.
For the time being, leniolisib phosphate is not recommended for the treatment of patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome.
